What should clinicians know about Invega Sustenna (paliperidone palmitate LAI)?

Invega Sustenna

Indication(s)

Schizophrenia; Schizoaffective Disorder

Dosing available as prefilled syringes

39 (injection volume of 0.25 ml) corresponds to a daily oral dose of paliperidone 3 mg
78 mg (injection volume of 0.5 ml) corresponds to a daily oral dose of paliperidone 3 mg
117 mg (injection volume of 0.75 ml) corresponds to a daily oral dose of paliperidone 6 mg
156 mg (injection volume of 1 ml) corresponds to a daily oral dose of paliperidone 9 mg
234 mg (injection volume of 1.5 ml) corresponds to a daily oral dose of paliperidone 12 mg

Recommended starting and maintenance dose

Recommended maintenance dose for treatment of schizophrenia is 117 mg.

Drug Metabolizing Enzyme

CYP3A4

Dosing exclusions

CrCL dosing:
For patients with mild renal impairment (CrCl >/= 50 mL/min to < 80 mL/min: Initiate Sustenna with a dose of 156 mg on treatment day 1, 117 mg one week later. Monthly maintenance dose of 78 mg ; adjust monthly maintenance dose based on tolerability and/or efficacy
Not recommended in patients with moderate or severe renal impairment (CrCl < 50 mL/min

Loading dose

Loading dose strategy is recommended after tolerability has been established with oral risperidone or paliperidone (for patients naïve to Invega Sustenna):On day 1 administer Invega Sustenna 234 mg in the deltoid.
One week later administer Invega Sustenna 156 mg in the deltoid per medication label, while using clinical judgment. (Published data suggests Invega Sustenna 234 mg for both initiation doses and maintenance is safe.)
Seven days is recommended for the second loading dose, but a window of 4-10 days is acceptable.
The first maintenance dose should be administered 5 weeks following the first (of 2) loading doses.Maintenance dose should be selected to correspond with appropriate oral dose equivalent (as detailed above).
The loading dose strategy should NOT be used for patients switching from one LAI to another, i.e., Aristada to Invega Sustenna. Detailed protocols for switching between LAIs have not been established, but it is recommended that there is overlap of 1-3 weeks when switching to oral paliperidone. Therefore, prescribers should stop the previous LAI and initiate the new LAI at targeted maintenance dose when possible.

Oral overlap

No oral supplementation is necessary.

Establishing tolerability

Prior to initiating Invega Sustenna, establish tolerability with oral paliperidone or risperidone.

Storage

Room temperature

Reconstitution or mixing

N/A

Injection site

Choose between the deltoid or gluteal muscle (for maintenance doses) based on the patient preference and body habitus. Both loading doses should be administered in the deltoid muscle.Rotate injection sites to avoid muscle hypertrophy, abscesses, and tissue damage by repeated, frequent injections at the same site.
For deltoid injections: For patients weighing less than 90 kg, the 1-inch, 23 gauge needle is recommended.
For patients weighing 90 kg or more, the 1 ½-inch, 22 gauge needle is recommended.
For gluteal injections:The recommended needle size for administration of Invega Sustenna into the gluteal muscle is the 1½-inch, 22 gauge needle regardless of patient weight.
Deltoid is specifically recommended for faster distribution during the initiation phase.

Injection interval

Every 4 weeks

Preparation

Shake the syringe vigorously for a minimum of 10 seconds to ensure a homogeneous suspension. Priming the syringe is recommended.

Administration considerations

Administer the injection within 5 minutes of shaking. Inject the entire contents intramuscularly slowly, deep into the selected deltoid or gluteal muscle of the patient.

Timing variations

For initiation dosing: the second initiation dose can be given within a 4 to 10 day window after the first injection.

To avoid a missed maintenance injection, patients may be given the injection up to 7 days before or after the monthly time point.

When a dose is missed

See this tip on how to manage missed doses of Invega Sustenna.
Monthly doses can be flexibly administered one week before or after the scheduled dose to avoid missed doses.

REMS

No